Long-Term Effects of Bone Marrow-Derived Mesenchymal Stem Cells in Dextran Sulfate Sodium-Induced Murine Chronic Colitis.
- Author:
Hyun Jung LEE
1
;
Sun Hee OH
;
Hui Won JANG
;
Ji Hee KWON
;
Kyoung Jin LEE
;
Chung Hee KIM
;
Soo Jung PARK
;
Sung Pil HONG
;
Jae Hee CHEON
;
Tae Il KIM
;
Won Ho KIM
Author Information
1. Department of Internal Medicine and Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea. taeilkim@yuhs.ac
- Publication Type:Original Article
- Keywords:
Bone marrow;
Mesenchymal stem cell;
Dextran sulfate sodium;
Chronic colitis;
Inflammatory bowel disease
- MeSH:
Animals;
Body Weight;
Bone Marrow;
Colitis*;
Colon;
Dextran Sulfate*;
Dextrans*;
Inflammation;
Inflammatory Bowel Diseases;
Interleukin-10;
Mesenchymal Stromal Cells*;
Mice;
Real-Time Polymerase Chain Reaction
- From:Gut and Liver
2016;10(3):412-419
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Bone marrow-derived mesenchymal stem cells (BM-MSCs) have shown beneficial effects in experimental colitis models, but the underlying mechanisms are not fully understood. We investigated the long-term effects of BM-MSCs, particularly in mice with chronic colitis. METHODS: Chronic colitis was induced by administering 3% dextran sulfate sodium (DSS) in a series of three cycles. BM-MSCs were injected intravenously into DSS-treated mice three times during the first cycle. On day 33, the therapeutic effects were evaluated with clinicopathologic profiles and histological scoring. Inflammatory mediators were measured with real-time polymerase chain reaction. RESULTS: Systemic infusion of BM-MSCs ameliorated the severity of colitis, and body weight restoration was significantly promoted in the BM-MSC-treated mice. In addition, BM-MSC treatment showed a sustained beneficial effect throughout the three cycles. Microscopic examination revealed that the mice treated with BM-MSCs had fewer inflammatory infiltrates, a lesser extent of inflammation, and less crypt structure damage compared with mice with DSS-induced colitis. Anti-inflammatory cytokine levels of interleukin-10 were significantly increased in the inflamed colons of BM-MSC-treated mice compared with DSS-induced colitis mice. CONCLUSIONS: Systemic infusion of BM-MSCs at the onset of disease exerted preventive and rapid recovery effects, with long-term immunosuppressive action in mice with repeated DSS-induced chronic colitis.
